deltatrials
Active Not Recruiting PHASE1 INTERVENTIONAL 1-arm NCT02687906

Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections (TANGOKIDS)

An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of a Single Dose Infusion of VABOMERE (Meropenem-Vaborbactam) in Pediatric Subjects From Birth to Less Than 18 Years of Age With Serious Bacterial Infections

Sponsor: Department of Health and Human Services

Conditions Bacterial Infections
Interventions Vabomere
Updated 18 times since 2017 Last updated: Jul 24, 2025 Started: Jul 31, 2016 Primary completion: Dec 31, 2025 Completion: Dec 31, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02687906, this PHASE1 trial focuses on Bacterial Infections and remains ongoing. Sponsored by Department of Health and Human Services, it has been updated 18 times since 2016, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Apr 2018 · 10 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Dec 2018 · 6 months · monthly snapshot~Dec 2018 – ~Feb 2020 · 14 months · monthly snapshot~Feb 2020 – ~Aug 2020 · 6 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Feb 2023 · 17 months · monthly snapshot~Feb 2023 – ~Oct 2023 · 8 months · monthly snapshot~Oct 2023 – ~Apr 2024 · 6 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Mar 2025 · 5 months · monthly snapshot~Mar 2025 – ~Aug 2025 · 5 months · monthly snapshot~Aug 2025 – present · 11 months · monthly snapshot

Change History

18 versions recorded

  1. Aug 2025 — Present [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  2. Mar 2025 — Aug 2025 [monthly]

    Recruiting PHASE1

  3. Oct 2024 — Mar 2025 [monthly]

    Recruiting PHASE1

  4. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE1

  5. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

▶ Show 13 earlier versions

  1. Apr 2024 — Jul 2024 [monthly]

    Recruiting PHASE1

  2. Oct 2023 — Apr 2024 [monthly]

    Recruiting PHASE1

  3. Feb 2023 — Oct 2023 [monthly]

    Recruiting PHASE1

  4. Sep 2021 — Feb 2023 [monthly]

    Recruiting PHASE1

  5. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  6. Aug 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  7. Feb 2020 — Aug 2020 [monthly]

    Recruiting PHASE1

  8. Dec 2018 — Feb 2020 [monthly]

    Recruiting PHASE1

  9. Jun 2018 — Dec 2018 [monthly]

    Recruiting PHASE1

  10. Apr 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

  11. Jun 2017 — Apr 2018 [monthly]

    Recruiting PHASE1

  12. Feb 2017 — Jun 2017 [monthly]

    Recruiting PHASE1

  13. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Jul 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Department of Health and Human Services
  • Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)
Data source: Melinta Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations